Zhejiang Xianju Pharmaceutical (002332.SZ) has obtained the domestic production drug registration certificate for misoprostol sodium tablets.

Zhejiang Xianju Pharmaceutical (002332.SZ) announced that the company has recently received the "Drug Registration Certificate" (Certificate Number: 2025S00441) issued by the National Medical Products Administration for its betaprost sodium tablets. The company's betaprost sodium tablets have been approved for registration. The indication for betaprost sodium tablets is to improve symptoms such as ulcers, intermittent claudication, pain, and sensation of cold caused by chronic arterial occlusive disease. The specifications of the betaprost sodium tablets applied for by the company this time are consistent with the specifications of the original drug that has been approved for market. The application was submitted according to the 4th class of chemical drugs.